TY - JOUR
T1 - Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus
AU - Meunier, Jean-Christophe
AU - Gottwein, Judith M
AU - Houghton, Michael
AU - Russell, Rodney S
AU - Emerson, Suzanne U
AU - Bukh, Jens
AU - Purcell, Robert H
PY - 2011
Y1 - 2011
N2 - We detected cross-reactive neutralizing antibodies (NtAb) against hepatitis C virus (HCV) in chimpanzees vaccinated with HCV-1 (genotype 1a) recombinant E1/E2 envelope glycoproteins. Five vaccinated chimpanzees, protected following HCV-1 challenge, were initially studied using the heterologous H77 (genotype 1a) HCVpp assay. All animals had developed NtAb after the second vaccination; 4 animals had reciprocal titers of ≥200 at the time of challenge. Using genotypes 1a-6a HCV pseudoparticles (HCVpp) and cell culture-derived HCV (HCVcc) assays, cross-reactive NtAb were detected against 1a, 4a, 5a, and 6a, with limited reactivity against 2a and 3a. Our study provides encouragement for the development of a recombinant envelope-based vaccine against hepatitis C.
AB - We detected cross-reactive neutralizing antibodies (NtAb) against hepatitis C virus (HCV) in chimpanzees vaccinated with HCV-1 (genotype 1a) recombinant E1/E2 envelope glycoproteins. Five vaccinated chimpanzees, protected following HCV-1 challenge, were initially studied using the heterologous H77 (genotype 1a) HCVpp assay. All animals had developed NtAb after the second vaccination; 4 animals had reciprocal titers of ≥200 at the time of challenge. Using genotypes 1a-6a HCV pseudoparticles (HCVpp) and cell culture-derived HCV (HCVcc) assays, cross-reactive NtAb were detected against 1a, 4a, 5a, and 6a, with limited reactivity against 2a and 3a. Our study provides encouragement for the development of a recombinant envelope-based vaccine against hepatitis C.
U2 - 10.1093/infdis/jir511
DO - 10.1093/infdis/jir511
M3 - Journal article
C2 - 21917891
SN - 0022-1899
VL - 204
SP - 1186
EP - 1190
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 8
ER -